Pashna Munshi

@MunshiPashna

Stem Cell Transplant physician. Live with empathy, passion, honesty and happiness!

Washington, DC
Vrijeme pridruživanja: kolovoz 2015.

Tweetovi

Blokirali ste korisnika/cu @MunshiPashna

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MunshiPashna

  1. proslijedio/la je Tweet

    #𝟳 𝗧𝗘𝗔𝗠𝗠 Antibiotic prophylaxis with levofloxacin in the first 3 months of induction therapy for myeloma is effective. We have changed our guidelines based on this trial. Also recommend Bactrim for PCP prophylaxis.

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet

    #𝟵 𝗠𝘆𝗲𝗹𝗼𝗺𝗮 𝗫𝗜 Intensification to get deeper response after induction does not improve survival. Important coz we see some centers delay transplant trying to get deeper response. We recommend ASCT after 3-4 cycles.

    Prikaži ovu nit
    Poništi
  3. 13. pro 2019.

    Older patients should not be denied AHCT with dose intense Mel without just cause. What about older DLBCL patients? Best tool to measure frailty and correlate outcomes in this population?

    Poništi
  4. proslijedio/la je Tweet

    At conferences, I use Inigo Montoya’s guide to Networking Success (Yes, really. Otherwise I always forget to say my name🤦🏻‍♀️) 1. Greeting 2. Name 3. Relevant personal connection 4. What to expect from the encounter

    Prikaži ovu nit
    Poništi
  5. proslijedio/la je Tweet
    5. pro 2019.
    Poništi
  6. proslijedio/la je Tweet
    5. pro 2019.

    What do the experts think will be the most important talks at this year’s ASH? Find out as 11 experts weigh in.

    Poništi
  7. proslijedio/la je Tweet
    1. pro 2019.
    Prikaži ovu nit
    Poništi
  8. proslijedio/la je Tweet
    26. lis 2019.

    Essential read, especially as a bone marrow transplanter caring for patients with chronic GvHD.

    Poništi
  9. proslijedio/la je Tweet

    Finally out! EU trial: dose 400 to 1200mg vs. 900mg BID for preemption in patients: Compare to US trial for refractory/resistant infection published in CID:

    , , i još njih 7
    Prikaži ovu nit
    Poništi
  10. proslijedio/la je Tweet
    16. ruj 2019.

    ASTCT will attend a congressional briefing tomorrow on Capitol Hill. Leading scientists will discuss CAR T-cell therapy, its development, how it works to treat blood cancer and issues with access within Medicaid. See the briefing flyer below for more information.

    Poništi
  11. 14. srp 2019.

    ⁩ and team validates findings of - patients with +NGS getting RIC do worse than MAC.

    Poništi
  12. 14. srp 2019.

    Exciting initiative and great symposium - MDS SIG ⁦⁩ ⁦

    Poništi
  13. 14. srp 2019.

    Is an 80-Hour Workweek Enough to Train a Doctor? Controversial subject as always, but I believe every bit of of those 30 hour calls has served me well today!!

    Poništi
  14. proslijedio/la je Tweet
    6. srp 2019.

    What is an allogeneic stem cell transplant? explains in this video.

    Poništi
  15. 23. velj 2019.
    Poništi
  16. 13. sij 2019.

    First patient 6mos out from First CAR-T treatment thanks to a great team!

    Poništi
  17. 11. sij 2019.

    3 Ways to Make Electronic Health Records Less Time-Consuming for Physicians. A far-fetched reality?

    Poništi
  18. proslijedio/la je Tweet
    Poništi
  19. proslijedio/la je Tweet
    21. velj 2018.

    Additional 💜 awardees honored today at the Myeloma Intergroup Meeting by 0702 Co-Chairs. Congratulations again to 0702 ERC members!

    Poništi
  20. 22. lis 2017.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·